PDA

Visualizza versione completa : Sanofi Aventis



surftrader
20-10-2005, 19.11.14
E' la dritta del 20 ottobre di Meglioli.
Personalmente mi trovo daccordo con lui,e' sicuramente interessante.
Mi sapete dire in che mercato e' quotata questa azione?
Grazie

ipcress
20-10-2005, 20.12.29
In Francia un titolo del CAC 40
Ciao

surftrader
20-10-2005, 23.11.38
In Sella ho solo l'Euronext Parigi quindi non posso operare su
questa azione........qualche selliano mi puo' confermare?
Grazie

peppyy
23-12-2006, 10.46.01
MOLTO MA MOLTO INTERESSANTE stop loss sotto 65 e camminare ,regalo di NATALE

redhawk
26-12-2006, 22.59.07
Io sono gi dentro da Ottobre e se riuscisse finalmente a sfondare con decisione i 70euro, gli spazi di risalita sarebbero elevati!

peppyy
27-12-2006, 15.46.57
MOLTO MA MOLTO INTERESSANTE stop loss sotto 65 e camminare ,regalo di NATALE
70 euriniiiii:D

redhawk
27-12-2006, 19.22.47
70 euriniiiii:D

speriamo sia la volta buona!

peppyy
05-01-2007, 10.11.27
MOLTO MA MOLTO INTERESSANTE stop loss sotto 65 e camminare ,regalo di NATALE
benone siamo a 71.5 :D

redhawk
08-01-2007, 19.47.12
Malone...siamo riscesi di brutto oggi! Ma che successo?

cbr20842,1
09-02-2007, 14.41.31
AP
Sanofi-Aventis Loses U.S. Patent Case
Friday February 9, 7:43 am ET Sanofi-Aventis Loses U.S. Patent Case Against 2 Generic Drugmakers Over Lovenox
PARIS (AP) -- French pharmaceutical company Sanofi-Aventis SA said Friday it lost a U.S. court case against two generic drugmakers that have been attempting to sell cheaper copies of Lovenox, its top-selling drug.Although the patent protecting Lovenox does not expire until 2012, Amphastar Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. have been planning to launch generic copies of the blood thinning drug in the United States.
The trial was to determine whether Sanofi-Aventis engaged in so-called inequitable conduct when it initially filed the Lovenox patent.
Sanofi-Aventis said it is evaluating its options for further legal recourse after the ruling by the U.S. District Court for the Central District of California.
Lovenox is the company's best-selling drug, with sales totaling euro2.15 billion ($2.79 billion) in 2005.
Shares of Sanofi-Aventis fell as much as 2.9 percent to euro65.80 ($85.48) in Paris.
Collins Stewart analyst Navid Malik said that while at the moment no generic drugmaker has regulatory approval to sell the anticoagulant in the U.S., Lovenox's protection has significantly diminished with the outcome of the trial.
Swiss private bank Vontobel said the risk of a generic version of Lovenox is real and makes an eventual takeover of Bristol-Myers Squibb Co. by Sanofi-Aventis ever more likely.
Proving inequitable conduct -- which may include the submission of incomplete documents when applying for a patent -- could invalidate the entire patent.
Still, generic drugmakers may have to struggle to get Lovenox copycats approved by the U.S. Food and Drug Administration. The drug, which is derived from pig intestines, requires a complex manufacturing process that is difficult to duplicate.
Lovenox is also under threat by generic drugmaker Momenta Pharmaceuticals Inc., which has teamed up with Sandoz, a unit of Swiss drugmaker Novartis AG. As well as Lovenox, Sanofi-Aventis is defending its second-best selling product, Plavix, in a U.S. court.